Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Acquisition to Immediately Benefit Gx Gross Margin
Tweet Send to a FriendGet Alerts PTX Hot Sheet
Price: $3.96 +2.06%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade PTX Now!
Canaccord Genuity reiterates a 'Buy' on Pernix Therapeutics (NYSE: PTX) price target of $14.00.
Analyst, Randall Stanicky, said, "Pernix announced after the close the acquisition of Great Southern Laboratories for $4.9 million. The acquisition adds manufacturing capabilities which PTX intends to use as it further expands its portfolio into OTC and prescription products. With ~$39 million in cash (Q1) and a stated intention to continue to look at business development opportunities, we expect PTX to stay active in its search for deals that diversify the revenue stream and support the P&L. Currently trading at ~12.0x 2013E EPS, we see risk/reward favorably given our robust 39% estimated 3-year EPS CAGR off 2011."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $7.50 yesterday, with a 52 week range of $5.90-$11.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "Pernix announced after the close the acquisition of Great Southern Laboratories for $4.9 million. The acquisition adds manufacturing capabilities which PTX intends to use as it further expands its portfolio into OTC and prescription products. With ~$39 million in cash (Q1) and a stated intention to continue to look at business development opportunities, we expect PTX to stay active in its search for deals that diversify the revenue stream and support the P&L. Currently trading at ~12.0x 2013E EPS, we see risk/reward favorably given our robust 39% estimated 3-year EPS CAGR off 2011."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $7.50 yesterday, with a 52 week range of $5.90-$11.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- KeyBanc Boosts La-Z-Boy (LZB) Price Target
- UPDATE: Howard Weil Upgrades LINN Energy (LINE) to Outperform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
